1-855-378-42281-855-378-4228
One of the outpatient rehab alternatives for clients in Middle Brook struggling with opioid abuse and addiction is opioid maintenance therapy. Some centers and doctors are authorized to dispense specific meds to opioid addicted clients, many of which are opioids also and are habit forming. With low doses the user doesn't experience high feelings and also doesn't experience intense cravings and isn't experiencing opioid withdrawal. Methadone is the first med used for this purpose, but there are alternative options currently to select from.
Methadone is an opiate and can be taken at an outpatient medical center certified to dispense the drug, that is taken on a daily basis as a pill or liquid. The cost of the drug is around one hundred and fifty dolloars a month. Buprenorphine is also an opiate based med, and is a pill often taken every other day. But unlike Methadone which can only be administered in highly well-regulated medical centers, Buprenorphine can be prescribed and administered in doctor's offices. The monthly cost of buprenorphine is about three hundred dollars per month for the generic version of the med. There is also a type of buprenorphine that contains the ingredient naloxone, which is a med which blocks the effects of opioids. Someone taking this version of the drug, also known as Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It too is taken on a daily basis, and costs approximately $450 a month. Naltrexone is an additional drug used in opioid maintenance therapy, but unlike the other medications mentioned it is an opioid blocker and isn't an opiate. A person has the choice to take this medication as a monthly injection, and that is called Vivitrol. As an opioid blocker, it prevents a person from experience high feelings from opioids, and in turn lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 per month.
For All Alcohol and Drug Rehab Centers In Middle Brook, Click Here.
